Cite
APA Citation
Yerushalmi, R., Eiermann, W., Rugo, H., Ettl, J., Hurvitz, S. A., Gonçalves, A., Miguel, M., Markova, D., Tudor, I., Blum, J., Hannah, A., & Litton, J. (n.d.). a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. Breast, 41, S12–. http://access.bl.uk/ark:/81055/vdc_100070082993.0x000029